EGFR and neoplasm: This potential for improved patient outcomes has been demonstrated in preclinical studies in the murine H1975-HGF xenograft model where greater tumor reductions and more durable disease control were observed when amivantamab was given in combination with lazertinib, a potent brain-penetrant third-generation EGFR TKI with efficacy against activating EGFR and T790M mutations, as compared to treatment with either agent alone33.